Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG
Rivastigmine Hexal has been authorised for dementia-related indications in the European market.
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH
EMA authorised rivastigmine Sandoz for dementia indications, including Alzheimer disease and Parkinson disease.
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine 1 A Pharma (rivastigmine) — 1 A Pharma GmbH
EMA authorises rivastigmine 1 A Pharma for Alzheimer's disease, dementia, and Parkinson's disease.
-
EMA approval · 2026-08-06EMA Authorised: Neuraceq (florbetaben (18F)) — Lantheus Germany GmbH
EMA authorised Neuraceq (florbetaben [18F]) for use in radionuclide imaging to support assessment of Alzheimer's disease, under Lantheus Ger…
-
EMA approval · 2026-08-05EMA Authorised: Leqembi (Lecanemab) — Eisai GmbH
The EMA has authorised Leqembi (lecanemab) for cognitive dysfunction and Alzheimer's disease, with Eisai GmbH as the marketing authorization…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-08EMA Authorised: Ebixa (memantine hydrochloride) — H. Lundbeck A/S
Memantine hydrochloride (Ebixa) has been authorised for use in Alzheimer disease in the European Union.
-
EMA approval · 2026-04-28EMA Authorised: Neuraceq (florbetaben (18F)) — Lantheus Germany GmbH
EMA has authorised Neuraceq (florbetaben 18F) for radionuclide imaging related to Alzheimer disease.
-
EMA approval · 2026-03-13EMA Authorised: Vizamyl (flutemetamol (18F)) — GE Healthcare AS
EMA authorised Vizamyl (flutemetamol (18F)) for radionuclide PET imaging in adults being evaluated for Alzheimer's disease.
-
EMA approval · 2026-02-26EMA Authorised: Kisunla (donanemab) — Eli Lilly Nederland B.V.
EMA authorised Kisunla (donanemab) for Alzheimer's disease and cognitive dysfunction in the European Union. Eli Lilly Nederland B.V. is the …
-
EMA approval · 2026-02-25EMA Authorised: DaTSCAN (ioflupane (123l)) — GE Healthcare B.V.
EMA authorised DaTSCAN, a radiopharmaceutical imaging agent (ioflupane I-123) by GE Healthcare B.V., for use in the diagnostic assessment of…
-
EMA approval · 2026-02-24EMA Authorised: Exelon (rivastigmine) — Novartis Europharm Limited
The European Medicines Agency authorised Exelon (rivastigmine) for dementia including Alzheimer's disease and Parkinson's disease, with Nova…
-
EMA approval · 2026-02-04EMA Authorised: Leqembi (Lecanemab) — Eisai GmbH
The European Medicines Agency has authorized Leqembi (lecanemab) by Eisai GmbH for the treatment of Alzheimer's disease, addressing cognitiv…
-
EMA approval · 2026-01-16EMA Authorised: Tauvid (Flortaucipir (18F)) — Eli Lilly Nederland B.V.
The EMA authorized Tauvid, a radiopharmaceutical PET imaging agent (flortaucipir F18) developed by Eli Lilly Nederland B.V. The product is i…
-
EMA approval · 2026-01-16EMA Authorised: Amyvid (florbetapir (18F)) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Amyvid (florbetapir (18F)) for radionuclide imaging. The marketing authorization holder is Eli Lill…
-
FDA approval · 2026-01-16FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)
The FDA approved a supplemental application for LEQEMBI (lecanemab) from Eisai Inc., related to its labeling/indication.
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG
Hexal AG's rivastigmine product has been authorized in the EU for dementia-related indications including Alzheimer's disease and Parkinson's…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH
The European Medicines Agency authorised Rivastigmine Sandoz (rivastigmine) for dementia indications, including Alzheimer's disease and Park…
-
EMA approval · 2026-01-16EMA Authorised: Rivastigmine 1 A Pharma (rivastigmine) — 1 A Pharma GmbH
The EMA authorised rivastigmine from 1 A Pharma GmbH for use in Alzheimer's disease, dementia, and Parkinson's disease.
-
FDA approval · 2025-12-15FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)
FDA page describing Eisai's supplemental application for LEQEMBI (lecanemab) and its regulatory submission status. The entry identifies the …
-
EMA approval · 2025-11-28EMA Authorised: Memantine Mylan (memantine hydrochloride) — Mylan Pharmaceuticals Limited
EMA authorised Memantine Mylan (memantine hydrochloride) for Alzheimer's disease. The marketing authorization holder is Mylan Pharmaceutical…
-
EMA approval · 2025-11-21EMA Authorised: Neuraceq (florbetaben (18F)) — Life Molecular Imaging GmbH
EMA authorised Neuraceq (florbetaben-18F) by Life Molecular Imaging GmbH for imaging beta-amyloid plaques in Alzheimer's disease.
-
EMA approval · 2025-10-09EMA Authorised: Memantine Accord (memantine hydrochloride) — Accord Healthcare S.L.U.
EMA authorised Memantine Accord (memantine hydrochloride) for the treatment of Alzheimer’s disease. The product is marketed by Accord Health…
-
FDA approval · 2025-08-29FDA Approved: LECANEMAB AUTOINJECTOR — Original Application (Eisai Inc.)
The FDA approved the Lecanemab Autoinjector (LECANEMAB-IRMB) in Eisai Inc.'s Original Application, enabling subcutaneous administration of l…
-
FDA approval · 2025-08-28FDA Approved: MEMANTINE HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
The FDA approved Macleods Pharmaceuticals Limited's memantine hydrochloride as a generic product under an Original Application. It is indica…
-
FDA approval · 2025-08-21FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)
The FDA approved Eisai’s supplemental application for LEQEMBI (lecanemab). The action updates its approved labeling/indication related to Al…